May 2, 2022

Antibe Therapeutics Announces Strategic Sale of Citagenix Subsidiary

– $6.5 million all-cash transaction, including milestone payments – Enables exclusive focus on drug pipeline TORONTO, CANADA — (May 2, 2022) — Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies that target inflammation, is pleased to announce the signing of a binding … Continued

more
April 25, 2022

Antibe Therapeutics to Present at the 2022 Bloom Burton & Co. Healthcare Investor Conference

TORONTO, CANADA — (April 25, 2022) – Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies that target inflammation, today announced its participation in the 2022 Bloom Burton & Co. Healthcare Investor Conference being held in person on May 2-3, 2022. Dan Legault, Antibe’s … Continued

more
February 14, 2022

Antibe Therapeutics Reports Q3 2022 Interim Financial and Operating Results

– Acute pain clinical program for otenaproxesul initiating this quarter – Ended quarter with a $59 million cash position TORONTO, CANADA — (February 14, 2022) – Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies that target inflammation, has filed its financial and … Continued

more

archives

Attention

This is an external link. Click “OK” to continue.

CANCEL OK